Biontech announces fourth quarter and full year 2023 financial results and corporate update

Advanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024 aiming for first oncology launch in 2026 and ten indication approvals by 2030 as part of biontech's strategy to develop combinatorial and synergistic therapeutic approaches entered strategic coll aborations with biotheus, dualitybio, medilink and oncoc4 to complement clinical oncology pipeline with innovative antibody-drug conjugate (adc) and immuno-modulatory programs annemarie hanekamp appointed as chief commercial officer effective july 1, 2024 delivered over 400 million covid-19 vaccine doses worldwide in 2023, including successfully launched xbb.1.5 variant-adapted monovalent covid-19 vaccine progressed three infectious disease vaccine candidates into clinical evaluation, leveraging biontech's mrna technology and expertise fourth quarter and full year 2023 revenues of €1.5 billion and €3.8 billion, respectively full year net profit of €0.9 billion and fully diluted earnings per share of €3.83 ($4.141) strong financial position with €17.7 billion in cash, cash equivalents and security investments 2024 revenue guidance of €2.5 billion to €3.1 billion   conference call and webcast scheduled for march 20, 2024, at 8:00 a.m. et (1:00 p.m.
BNTX Ratings Summary
BNTX Quant Ranking